Department of Physiology and Biophysics, Weill Cornell Medicine , New York, NY, USA.
Graduate Program in Physiology, Biophysics and Systems Biology, Weill Cornell Graduate School of Medical Sciences. New York, NY, USA.
J Gen Physiol. 2023 Apr 3;155(4). doi: 10.1085/jgp.202213247. Epub 2023 Feb 10.
A perennial problem encountered when using small molecules (drugs) to manipulate cell or protein function is to assess whether observed changes in function result from specific interactions with a desired target or from less specific off-target mechanisms. This is important in laboratory research as well as in drug development, where the goal is to identify molecules that are unlikely to be successful therapeutics early in the process, thereby avoiding costly mistakes. We pursued this challenge from the perspective that many bioactive molecules (drugs) are amphiphiles that alter lipid bilayer elastic properties, which may cause indiscriminate changes in membrane protein (and cell) function and, in turn, cytotoxicity. Such drug-induced changes in bilayer properties can be quantified as changes in the monomer↔dimer equilibrium for bilayer-spanning gramicidin channels. Using this approach, we tested whether molecules in the Pathogen Box (a library of 400 drugs and drug-like molecules with confirmed activity against tropical diseases released by Medicines for Malaria Venture to encourage the development of therapies for neglected tropical diseases) are bilayer modifiers. 32% of the molecules in the Pathogen Box were bilayer modifiers, defined as molecules that at 10 µM shifted the monomer↔dimer equilibrium toward the conducting dimers by at least 50%. Correlation analysis of the molecules' reported HepG2 cell cytotoxicity to bilayer-modifying potency, quantified as the shift in the gramicidin monomer↔dimer equilibrium, revealed that molecules producing <25% change in the equilibrium had significantly lower probability of being cytotoxic than molecules producing >50% change. Neither cytotoxicity nor bilayer-modifying potency (quantified as the shift in the gramicidin monomer↔dimer equilibrium) was well predicted by conventional physico-chemical descriptors (hydrophobicity, polar surface area, etc.). We conclude that drug-induced changes in lipid bilayer properties are robust predictors of the likelihood of membrane-mediated off-target effects, including cytotoxicity.
当使用小分子(药物)来操纵细胞或蛋白质功能时,一个长期存在的问题是评估观察到的功能变化是否是由于与所需靶标的特异性相互作用,还是由于非特异性的脱靶机制引起的。这在实验室研究和药物开发中都很重要,因为目标是在早期过程中识别不太可能成功的治疗分子,从而避免昂贵的错误。我们从许多生物活性分子(药物)是改变脂质双层弹性特性的两亲分子的角度来解决这一挑战,这可能导致膜蛋白(和细胞)功能的无差别变化,并进而导致细胞毒性。这种药物引起的双层性质变化可以通过改变跨双层的短杆菌肽通道的单体↔二聚体平衡来定量。使用这种方法,我们测试了病原体盒(由疟疾药物 Venture 发布的 400 种药物和类药物分子库,旨在鼓励开发治疗被忽视的热带病的疗法)中的分子是否是双层修饰剂。病原体盒中的 32%的分子是双层修饰剂,定义为在 10µM 时至少将单体↔二聚体平衡向导电二聚体移动 50%的分子。报告的 HepG2 细胞细胞毒性与双层修饰效力的相关性分析(定量为短杆菌肽单体↔二聚体平衡的移动)表明,平衡变化产生<25%变化的分子比平衡变化产生>50%变化的分子具有更低的细胞毒性可能性。毒性和双层修饰效力(定量为短杆菌肽单体↔二聚体平衡的移动)都不能很好地被传统的物理化学描述符(疏水性、极性表面积等)预测。我们得出的结论是,药物引起的脂质双层性质变化是膜介导的脱靶效应(包括细胞毒性)的可能性的可靠预测因子。